Loading…
Lobbying Spend
—
Filings
5
Firms Hired
1
Active Period
2012–2013
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
American Research and Competitiveness Act of 2011
2013 · second_quarter · Firm: FORBES-TATE
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement [Medicare Prescription Drug Act of 2003]; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; issues related to H.R. 942 - American Research and Competitiveness Act of 2011 (112th Congress).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 942
American Research and Competitiveness Act of 2011
2013 · first_quarter · Firm: FORBES-TATE
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement [Medicare Prescription Drug Act of 2003]; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; H.R. 942 - American Research and Competitiveness Act of 2011.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 942
Intellectual Property and Process Patent Issues- HR 1908, Patent Reform Act (all provisions).
Client expense: — · Firm income: $50,000
Matched citations: HR 1908
To specify the priority of the obligations of the United States Government if the debt ceiling is reached, to provide for an emergency appropriation of funds to pay for certain defense and national security obligations during a gap in funding, and for other purposes.
2012 · fourth_quarter · Firm: FORBES-TATE
Intellectual Property and Process Patent Issues- HR 1908, Patent Reform Act (all provisions).
Client expense: — · Firm income: $40,000
Matched citations: HR 1908
American Research and Competitiveness Act of 2011
2012 · fourth_quarter · Firm: FORBES-TATE
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement [Medicare Prescription Drug Act of 2003]; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; H.R. 942 - American Research and Competitiveness Act of 2011.
Client expense: — · Firm income: $40,000
Matched citations: H.R. 942
To specify the priority of the obligations of the United States Government if the debt ceiling is reached, to provide for an emergency appropriation of funds to pay for certain defense and national security obligations during a gap in funding, and for other purposes.
2012 · third_quarter · Firm: FORBES-TATE
Intellectual Property and Process Patent Issues- HR 1908, Patent Reform Act (all provisions).
Client expense: — · Firm income: $20,000
Matched citations: HR 1908
American Research and Competitiveness Act of 2011
2012 · third_quarter · Firm: FORBES-TATE
Implementation of P.L. 108-173, matters related to Medicare and Medicaid Coverage and Reimbursement [Medicare Prescription Drug Act of 2003]; issues relating to Prescription Drug User Fee Act and ASP +6; issues related to comparative effectiveness and follow-on biologics, issues related to FDA repeal of Avastin; issues related to coverage of Lucentis and Avastin; H.R. 942 - American Research and Competitiveness Act of 2011.
Client expense: — · Firm income: $20,000
Matched citations: H.R. 942
To specify the priority of the obligations of the United States Government if the debt ceiling is reached, to provide for an emergency appropriation of funds to pay for certain defense and national security obligations during a gap in funding, and for other purposes.
2012 · third_quarter · Firm: FORBES-TATE
Intellectual Property and Process Patent Issues--HR 1908, Patent Reform Act; implementation of PL 108-173, matters related to Medicare and Medicaid coverage and reimbursement; issues relating to Precription Drug User Fee Act and ASP+6; issue related to follow-on biologics; issues related to FDA repeal of Avastin; issues related to coverage of Luncentis and Avastin, HR 942 - American Research and Competitiveness Act of 2011.
Client expense: — · Firm income: —
Matched citations: HR 1908
To specify the priority of the obligations of the United States Government if the debt ceiling is reached, to provide for an emergency appropriation of funds to pay for certain defense and national security obligations during a gap in funding, and for other purposes.
2012 · third_quarter · Firm: FORBES-TATE
Intellectual Property and Process Patent Issues--HR 1908, Patent Reform Act; implementation of PL 108-173, matters related to Medicare and Medicaid coverage and reimbursement; issues relating to Precription Drug User Fee Act and ASP+6; issue related to follow-on biologics; issues related to FDA repeal of Avastin; issues related to coverage of Luncentis and Avastin, HR 942 - American Research and Competitiveness Act of 2011.
Client expense: — · Firm income: —
Matched citations: HR 1908
American Research and Competitiveness Act of 2011
2012 · third_quarter · Firm: FORBES-TATE
Intellectual Property and Process Patent Issues--HR 1908, Patent Reform Act; implementation of PL 108-173, matters related to Medicare and Medicaid coverage and reimbursement; issues relating to Precription Drug User Fee Act and ASP+6; issue related to follow-on biologics; issues related to FDA repeal of Avastin; issues related to coverage of Luncentis and Avastin, HR 942 - American Research and Competitiveness Act of 2011.
Client expense: — · Firm income: —
Matched citations: HR 942
American Research and Competitiveness Act of 2011
2012 · third_quarter · Firm: FORBES-TATE
Intellectual Property and Process Patent Issues--HR 1908, Patent Reform Act; implementation of PL 108-173, matters related to Medicare and Medicaid coverage and reimbursement; issues relating to Precription Drug User Fee Act and ASP+6; issue related to follow-on biologics; issues related to FDA repeal of Avastin; issues related to coverage of Luncentis and Avastin, HR 942 - American Research and Competitiveness Act of 2011.
Client expense: — · Firm income: —
Matched citations: HR 942
Source: Senate LDA